ATRA

(redirected from all-transretinoic acid)

ATRA

A vitamin-A analogue used to manage acute promelocytic leukaemia, with the translocation t(15;17) or typical PML-RAR gene rearrangement, as it prompts the leukaemic cells to maturation.

Adverse effects
Headaches, dry skin, mouth and eyes, nausea, bone pain.
References in periodicals archive ?
The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression.
She was treated with all-transretinoic acid (ATRA) and arsenic trioxide (ATO) immediately.
One case report described a patient with acute promyelocytic leukemia who was treated with all-transretinoic acid, daunomycin, cytarabine, and a short course of dexamethasone, and was diagnosed with AVN 2 years after the cessation of chemotherapy.
All-transretinoic acid (ATRA), a vitamin A derivative, binds to the RARA site of the PML-RARA fusion protein in APL cells and allows the leukemic promyelocytes to differentiate into mature granulocytes.
Li, "All-transretinoic acid regulates Th1/Th2 balance in CD4+ T cells when GATA-3 is deficient," Biomedical and Environmental Sciences, vol.
All-transretinoic acid (atRA), a biologically active metabolite of vitamin A (VA), has been shown to regulate the gene expression of components of rennin angiotensin system, including renin, angiotensin-converting enzyme, angiotensin II, and its type 1 receptor in animal studies [4].
Sekula et al., "G0S2 is an all-transretinoic acid target gene," International Journal of Oncology, vol.
Yu et al., "Effects of all-transretinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research," Neuro Toxicology, vol.
Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital.
(26-27) 13-cis-Retinoic acid increases the event-free survival of children with high-risk neuroblastoma, and ATRA (all-transretinoic acid) has recently become an important part of Acute Promyelocytic Leukemia (APL) treatment (28).
Treatment of the monocytes with [10.sup.-7] M all-transretinoic acid decreased the expression of MMP-9, and combined treatment with both all-trans-retinoic acid and P.

Full browser ?